Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug
Aim(s): We aimed to identify distinctive genomic alterations associated with benefit from SU and/or EVE treatment in patients with pNETs, by comparing ER to PO. Pts who achieved an objective radiological response together with those with a progression-free survival (PFS) beyond the median reported in the landmark trials were included in the ER group. Pts with a similar PFS to the placebo groups in the pivotal trials were classified as PO.
Materials and methods: Thirty-one pts were screened; following review of availability of the formalin-fixed paraffin embedded (FFPE) samples, 12 were found eligible to proceed with DNA extraction and sequencing. Paired DNA extracted from tumour (T) and non-T or blood was obtained. Two cases did not pass the quality check threshold for variant calling analysis (VCA).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Jorge Barriuso
To read results and conclusion, please login ...
Further abstracts you may be interested in